Royalty Pharma (RPRX) has had the highest return this year by a large-cap US stock in the Pharmaceuticals Industry, returning 39.8%.
| ASSET | YEAR | % RETURN |
|---|---|---|
Royalty Pharma (RPRX) | 2025 | 39.82% |
Novartis AG ADR (NVS) | 2025 | 31.37% |
Johnson & Johnson (JNJ) | 2025 | 26.72% |
GlaxoSmithKline PLC ADR (GSK) | 2025 | 21.4% |
Takeda Pharmaceutical Co Ltd ADR (TAK) | 2025 | 14.24% |
AstraZeneca PLC ADR (AZN) | 2025 | 14.08% |
Sanofi ADR (SNY) | 2025 | -1.58% |
Pfizer (PFE) | 2025 | -6.4% |
Eli Lilly and (LLY) | 2025 | -6.63% |
Dr Reddy’s Laboratories Ltd ADR (RDY) | 2025 | -9.09% |
Zoetis (ZTS) | 2025 | -12.11% |
Teva Pharma Industries Ltd ADR (TEVA) | 2025 | -16.75% |
Merck (MRK) | 2025 | -19.4% |
Bristol-Myers Squibb (BMY) | 2025 | -19.75% |
Viatris (VTRS) | 2025 | -20.38% |
Novo Nordisk A-S (NVO) | 2025 | -34.99% |
Large-cap stocks are treated as having a market cap of $10B+.
